Amid the expected positive clinical trial results, Legend Biotech has also reiterated plans to achieve profitability in 2026.
High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) ...
Geron Corporation (NASDAQ:GERN) advances cancer research as part of broader discussions linked to the nasdaq index.
Purple Biotech Ltd. announced it is advancing NT219, a novel drug aimed at overcoming tumor resistance to therapy, into a Phase 2 clinical trial for patients with recurrent/metastatic squamous cell ...
SAN DIEGO and CALGARY, AB, Feb. 19, 2025 /PRNewswire/ -- Oncolytics Biotech (ONCY) ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, ...
Oncolytics Biotech Inc. (NASDAQ:ONCY) is included in our list of the stocks under $1 that will explode. Oncolytics Biotech Inc. (NASDAQ:ONCY) shared a leadership update on January 7, 2026. With the ...
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
This meeting will serve as a kick-off for the National Academies consensus study Biotechnology Capabilities for National Security Needs--Leveraging Advances in Transdisciplinary Biotechnology. This me ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results